Cargando…

The Dose Response Multicentre Investigation on Fluid Assessment (DoReMIFA) in critically ill patients

BACKGROUND: The previously published “Dose Response Multicentre International Collaborative Initiative (DoReMi)” study concluded that the high mortality of critically ill patients with acute kidney injury (AKI) was unlikely to be related to an inadequate dose of renal replacement therapy (RRT) and o...

Descripción completa

Detalles Bibliográficos
Autores principales: Garzotto, F., Ostermann, M., Martín-Langerwerf, D., Sánchez-Sánchez, M., Teng, J., Robert, R., Marinho, A., Herrera-Gutierrez, M. E., Mao, H. J., Benavente, D., Kipnis, E., Lorenzin, A., Marcelli, D., Tetta, C., Ronco, C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4918119/
https://www.ncbi.nlm.nih.gov/pubmed/27334608
http://dx.doi.org/10.1186/s13054-016-1355-9
_version_ 1782439060470497280
author Garzotto, F.
Ostermann, M.
Martín-Langerwerf, D.
Sánchez-Sánchez, M.
Teng, J.
Robert, R.
Marinho, A.
Herrera-Gutierrez, M. E.
Mao, H. J.
Benavente, D.
Kipnis, E.
Lorenzin, A.
Marcelli, D.
Tetta, C.
Ronco, C.
author_facet Garzotto, F.
Ostermann, M.
Martín-Langerwerf, D.
Sánchez-Sánchez, M.
Teng, J.
Robert, R.
Marinho, A.
Herrera-Gutierrez, M. E.
Mao, H. J.
Benavente, D.
Kipnis, E.
Lorenzin, A.
Marcelli, D.
Tetta, C.
Ronco, C.
author_sort Garzotto, F.
collection PubMed
description BACKGROUND: The previously published “Dose Response Multicentre International Collaborative Initiative (DoReMi)” study concluded that the high mortality of critically ill patients with acute kidney injury (AKI) was unlikely to be related to an inadequate dose of renal replacement therapy (RRT) and other factors were contributing. This follow-up study aimed to investigate the impact of daily fluid balance and fluid accumulation on mortality of critically ill patients without AKI (N-AKI), with AKI (AKI) and with AKI on RRT (AKI-RRT) receiving an adequate dose of RRT. METHODS: We prospectively enrolled all consecutive patients admitted to 21 intensive care units (ICUs) from nine countries and collected baseline characteristics, comorbidities, severity of illness, presence of sepsis, daily physiologic parameters and fluid intake-output, AKI stage, need for RRT and survival status. Daily fluid balance was computed and fluid overload (FO) was defined as percentage of admission body weight (BW). Maximum fluid overload (MFO) was the peak value of FO. RESULTS: We analysed 1734 patients. A total of 991 (57 %) had N-AKI, 560 (32 %) had AKI but did not have RRT and 183 (11 %) had AKI-RRT. ICU mortality was 22.3 % in AKI patients and 5.6 % in those without AKI (p < 0.0001). Progressive fluid accumulation was seen in all three groups. Maximum fluid accumulation occurred on day 2 in N-AKI patients (2.8 % of BW), on day 3 in AKI patients not receiving RRT (4.3 % of BW) and on day 5 in AKI-RRT patients (7.9 % of BW). The main findings were: (1) the odds ratio (OR) for hospital mortality increased by 1.075 (95 % confidence interval 1.055–1.095) with every 1 % increase of MFO. When adjusting for severity of illness and AKI status, the OR changed to 1.044. This phenomenon was a continuum and independent of thresholds as previously reported. (2) Multivariate analysis confirmed that the speed of fluid accumulation was independently associated with ICU mortality. (3) Fluid accumulation increased significantly in the 3-day period prior to the diagnosis of AKI and peaked 3 days later. CONCLUSIONS: In critically ill patients, the severity and speed of fluid accumulation are independent risk factors for ICU mortality. Fluid balance abnormality precedes and follows the diagnosis of AKI. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13054-016-1355-9) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4918119
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-49181192016-06-24 The Dose Response Multicentre Investigation on Fluid Assessment (DoReMIFA) in critically ill patients Garzotto, F. Ostermann, M. Martín-Langerwerf, D. Sánchez-Sánchez, M. Teng, J. Robert, R. Marinho, A. Herrera-Gutierrez, M. E. Mao, H. J. Benavente, D. Kipnis, E. Lorenzin, A. Marcelli, D. Tetta, C. Ronco, C. Crit Care Research BACKGROUND: The previously published “Dose Response Multicentre International Collaborative Initiative (DoReMi)” study concluded that the high mortality of critically ill patients with acute kidney injury (AKI) was unlikely to be related to an inadequate dose of renal replacement therapy (RRT) and other factors were contributing. This follow-up study aimed to investigate the impact of daily fluid balance and fluid accumulation on mortality of critically ill patients without AKI (N-AKI), with AKI (AKI) and with AKI on RRT (AKI-RRT) receiving an adequate dose of RRT. METHODS: We prospectively enrolled all consecutive patients admitted to 21 intensive care units (ICUs) from nine countries and collected baseline characteristics, comorbidities, severity of illness, presence of sepsis, daily physiologic parameters and fluid intake-output, AKI stage, need for RRT and survival status. Daily fluid balance was computed and fluid overload (FO) was defined as percentage of admission body weight (BW). Maximum fluid overload (MFO) was the peak value of FO. RESULTS: We analysed 1734 patients. A total of 991 (57 %) had N-AKI, 560 (32 %) had AKI but did not have RRT and 183 (11 %) had AKI-RRT. ICU mortality was 22.3 % in AKI patients and 5.6 % in those without AKI (p < 0.0001). Progressive fluid accumulation was seen in all three groups. Maximum fluid accumulation occurred on day 2 in N-AKI patients (2.8 % of BW), on day 3 in AKI patients not receiving RRT (4.3 % of BW) and on day 5 in AKI-RRT patients (7.9 % of BW). The main findings were: (1) the odds ratio (OR) for hospital mortality increased by 1.075 (95 % confidence interval 1.055–1.095) with every 1 % increase of MFO. When adjusting for severity of illness and AKI status, the OR changed to 1.044. This phenomenon was a continuum and independent of thresholds as previously reported. (2) Multivariate analysis confirmed that the speed of fluid accumulation was independently associated with ICU mortality. (3) Fluid accumulation increased significantly in the 3-day period prior to the diagnosis of AKI and peaked 3 days later. CONCLUSIONS: In critically ill patients, the severity and speed of fluid accumulation are independent risk factors for ICU mortality. Fluid balance abnormality precedes and follows the diagnosis of AKI. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13054-016-1355-9) contains supplementary material, which is available to authorized users. BioMed Central 2016-06-23 2016 /pmc/articles/PMC4918119/ /pubmed/27334608 http://dx.doi.org/10.1186/s13054-016-1355-9 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Garzotto, F.
Ostermann, M.
Martín-Langerwerf, D.
Sánchez-Sánchez, M.
Teng, J.
Robert, R.
Marinho, A.
Herrera-Gutierrez, M. E.
Mao, H. J.
Benavente, D.
Kipnis, E.
Lorenzin, A.
Marcelli, D.
Tetta, C.
Ronco, C.
The Dose Response Multicentre Investigation on Fluid Assessment (DoReMIFA) in critically ill patients
title The Dose Response Multicentre Investigation on Fluid Assessment (DoReMIFA) in critically ill patients
title_full The Dose Response Multicentre Investigation on Fluid Assessment (DoReMIFA) in critically ill patients
title_fullStr The Dose Response Multicentre Investigation on Fluid Assessment (DoReMIFA) in critically ill patients
title_full_unstemmed The Dose Response Multicentre Investigation on Fluid Assessment (DoReMIFA) in critically ill patients
title_short The Dose Response Multicentre Investigation on Fluid Assessment (DoReMIFA) in critically ill patients
title_sort dose response multicentre investigation on fluid assessment (doremifa) in critically ill patients
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4918119/
https://www.ncbi.nlm.nih.gov/pubmed/27334608
http://dx.doi.org/10.1186/s13054-016-1355-9
work_keys_str_mv AT garzottof thedoseresponsemulticentreinvestigationonfluidassessmentdoremifaincriticallyillpatients
AT ostermannm thedoseresponsemulticentreinvestigationonfluidassessmentdoremifaincriticallyillpatients
AT martinlangerwerfd thedoseresponsemulticentreinvestigationonfluidassessmentdoremifaincriticallyillpatients
AT sanchezsanchezm thedoseresponsemulticentreinvestigationonfluidassessmentdoremifaincriticallyillpatients
AT tengj thedoseresponsemulticentreinvestigationonfluidassessmentdoremifaincriticallyillpatients
AT robertr thedoseresponsemulticentreinvestigationonfluidassessmentdoremifaincriticallyillpatients
AT marinhoa thedoseresponsemulticentreinvestigationonfluidassessmentdoremifaincriticallyillpatients
AT herreragutierrezme thedoseresponsemulticentreinvestigationonfluidassessmentdoremifaincriticallyillpatients
AT maohj thedoseresponsemulticentreinvestigationonfluidassessmentdoremifaincriticallyillpatients
AT benavented thedoseresponsemulticentreinvestigationonfluidassessmentdoremifaincriticallyillpatients
AT kipnise thedoseresponsemulticentreinvestigationonfluidassessmentdoremifaincriticallyillpatients
AT lorenzina thedoseresponsemulticentreinvestigationonfluidassessmentdoremifaincriticallyillpatients
AT marcellid thedoseresponsemulticentreinvestigationonfluidassessmentdoremifaincriticallyillpatients
AT tettac thedoseresponsemulticentreinvestigationonfluidassessmentdoremifaincriticallyillpatients
AT roncoc thedoseresponsemulticentreinvestigationonfluidassessmentdoremifaincriticallyillpatients
AT thedoseresponsemulticentreinvestigationonfluidassessmentdoremifaincriticallyillpatients
AT garzottof doseresponsemulticentreinvestigationonfluidassessmentdoremifaincriticallyillpatients
AT ostermannm doseresponsemulticentreinvestigationonfluidassessmentdoremifaincriticallyillpatients
AT martinlangerwerfd doseresponsemulticentreinvestigationonfluidassessmentdoremifaincriticallyillpatients
AT sanchezsanchezm doseresponsemulticentreinvestigationonfluidassessmentdoremifaincriticallyillpatients
AT tengj doseresponsemulticentreinvestigationonfluidassessmentdoremifaincriticallyillpatients
AT robertr doseresponsemulticentreinvestigationonfluidassessmentdoremifaincriticallyillpatients
AT marinhoa doseresponsemulticentreinvestigationonfluidassessmentdoremifaincriticallyillpatients
AT herreragutierrezme doseresponsemulticentreinvestigationonfluidassessmentdoremifaincriticallyillpatients
AT maohj doseresponsemulticentreinvestigationonfluidassessmentdoremifaincriticallyillpatients
AT benavented doseresponsemulticentreinvestigationonfluidassessmentdoremifaincriticallyillpatients
AT kipnise doseresponsemulticentreinvestigationonfluidassessmentdoremifaincriticallyillpatients
AT lorenzina doseresponsemulticentreinvestigationonfluidassessmentdoremifaincriticallyillpatients
AT marcellid doseresponsemulticentreinvestigationonfluidassessmentdoremifaincriticallyillpatients
AT tettac doseresponsemulticentreinvestigationonfluidassessmentdoremifaincriticallyillpatients
AT roncoc doseresponsemulticentreinvestigationonfluidassessmentdoremifaincriticallyillpatients
AT doseresponsemulticentreinvestigationonfluidassessmentdoremifaincriticallyillpatients